Sugi Predict

Sugi Predict / Compounds / SCHEMBL69223

SCHEMBL69223

SCHEMBL69223

CC(C)C[C@H](C(=O)O)N(C)C(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 4/20 0.48
▸ MMP13 P45452 1/20 0.38
▸ REN P00797 1/20 0.37
▸ CTSL P07711 1/20 0.36
▸ CTSB P07858 1/20 0.36
▸ CTSS P25774 1/20 0.36
▸ CTSK P43235 1/20 0.36
▸ RNPEP Q9H4A4 1/20 0.34
▸ SLC7A5 Q01650 1/20 0.34
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA7 P43166 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ CPA1 P15085 1/20 0.33
▸ HDAC1 Q13547 1/20 0.32
▸ HDAC2 Q92769 1/20 0.32
▸ HDAC6 Q9UBN7 1/20 0.32
▸ MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL67031 1.00 AAK1 (0.48) AAK1MMP13RENCTSLCTSB
SCHEMBL38056 1.00 AAK1 (0.48) AAK1MMP13RENCTSLCTSB
Water SCHEMBL3825021 0.98 AAK1 (0.47) AAK1MMP13RENCTSLCTSB
Ammonia Solution, Strong SCHEMBL28471283 0.98 AAK1 (0.47) AAK1MMP13RENCTSLCTSB
Lactic Acid SCHEMBL27487871 0.95 AAK1 (0.46) AAK1MMP13RENCTSLCTSB
SCHEMBL31191282 0.89 AAK1 (0.40) AAK1MMP13RENCTSLCTSB
SCHEMBL31036506 0.89 AAK1 (0.40) AAK1MMP13RENCTSLCTSB
SCHEMBL31522778 0.87 AAK1 (0.41) AAK1MMP13RENCTSLCTSB
SCHEMBL30639575 0.86 AAK1 (0.44) AAK1MMP13RENCTSLCTSB
SCHEMBL27032933 0.86 AAK1 (0.44) AAK1MMP13RENCTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120192379-A Marine cyclic peptide and synthesis method and application thereof 内蒙古大学 2025-06-24 — — CN claimed
CN-103965299-B A kind of ring pentapeptide and synthetic method thereof and application 暨南大学 2016-07-13 — — CN claimed
CN-103965299-A Cyclic pentapeptide as well as synthetic method and application thereof UNIV JINAN 2014-08-06 — — CN claimed
EP-4225762-B1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2026-05-27 — — EP disclosed
US-12612416-B2 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2026-04-28 — — US disclosed
EP-4612156-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
US-20250243196-A1 CITRON KINASE INHIBITORS THE CLEVELAND CLINIC FOUNDATION 2025-07-31 — — US disclosed
CN-120192379-A Marine cyclic peptide and synthesis method and application thereof 内蒙古大学 2025-06-24 — — CN disclosed
WO-2024258613-A9 TETRACHLOROVANCOMYCIN AND DERIVATIVES THE SCRIPPS RESEARCH INSTITUTE (US) 2025-05-30 — — WO disclosed
WO-2024258613-A2 TETRACHLOROVANCOMYCIN AND DERIVATIVES THE SCRIPPS RESEARCH INSTITUTE (US) 2024-12-19 — — WO disclosed
US-20240368096-A1 Fused Heterobicyclic Antiviral Agents ENANTA PHARMACEUTICALS, INC. 2024-11-07 — — US disclosed
US-7345034-B2 Azacyclosteroid histamine-3 receptor ligands ABBOTT LABORATORIES (US) 2008-03-18 — — US disclosed
EP-1735332-A1 AZACYCLOSTEROID HISTAMINE-3 RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2006-12-27 — — EP disclosed
US-20050245495-A1 Azacyclosteroid histamine-3 receptor ligands ABBOTT LABORATORIES 2005-11-03 — — US disclosed
WO-2005100377-A1 AZACYCLOSTEROID HISTAMINE-3 RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2005-10-27 — — WO disclosed
US-20050227953-A1 Azacyclosteroid histamine-3 receptor ligands ABBVIE INC. 2005-10-13 — — US disclosed
US-6458781-B1 BLOCKERS CALCIUM CHANNEL ANTAGONISTS FOR STROKES, BRAIN DISORDERS WARNER-LAMBERT COMPANY 2002-10-01 — — US disclosed
US-6399629-B1 PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY MICROCIDE PHARMACEUTICALS, INC. 2002-06-04 — — US disclosed
WO-2000001714-A1 EFFLUX PUMP INHIBITORS MICROCIDE PHARMACEUTICALS, INC. (US) 2000-01-13 — — WO disclosed
WO-1999055688-A1 SUBSTITUTED DIARYLALKYL AMIDES AS CALCIUM CHANNEL ANTAGONISTS WARNER-LAMBERT COMPANY (US) 1999-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368096-A1 Fused Heterobicyclic Antiviral Agents HAVCR2, HDGF, SLC10A1 AAK1 4533/4885MMP13 2698/4885REN 2666/4885
US-20050227953-A1 Azacyclosteroid histamine-3 receptor ligands HRH4, HRH3, HRH2 AAK1 3144/4885MMP13 2776/4885REN 750/4885
US-12612416-B2 Modulators of cystic fibrosis transmembrane conductance regulator CFTR, CLCN2, CLIC1 AAK1 4659/4885MMP13 2194/4885REN 800/4885
US-20250243196-A1 CITRON KINASE INHIBITORS CHEK2, CILK1, DCK AAK1 436/4885MMP13 2733/4885REN 4031/4885
US-20050245495-A1 Azacyclosteroid histamine-3 receptor ligands HRH4, HRH3, HRH2 AAK1 3144/4885MMP13 2776/4885REN 750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.